| abstract |
This refers to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia. Claim 1: A peptide compound having the formula (1): Tza-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-X¹⁰-Ser-Lys-Gln-X¹⁴-Glu-Ser-Arg-Arg- Ala-Gln-X²¹-Phe-lle-Glu-Trp-Leu-Leu-Ala-X²⁹-Gly-Pro-Glu-Ser-Gly-Ala-Pro-Pro-Pro-Ser-R¹ (1) X¹⁰ represents a remainder of amino acid selected from Tyr, Leu, Val, lle, Phe, Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine, Cyclohexylglycine and tert-Leucine; X¹⁴ represents an amino acid residue selected from Leu and Nle; X²¹ represents an amino acid residue selected from Asp and Glu; X²⁹ represents an amino acid residue selected from Gly and Thr; R¹ represents OH or NH₂; or a salt or solvate thereof. |